Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5327618 | 0.86 | GLA (0.38) | KMT2AALDH1A1RAB9AMEN1MAPT | |
| SCHEMBL5328503 | 0.82 | ADRA1D (0.40) | KMT2ARAB9ATP53ADRA1A | |
| SCHEMBL5330704 | 0.82 | SMN1; SMN2 (0.43) | KMT2AALDH1A1RAB9AMEN1TP53 | |
| SCHEMBL4994479 | 0.81 | KMT2A (0.36) | KMT2AALDH1A1RAB9AMEN1HPGD | |
| Bicarbonate SCHEMBL4976269 | 0.80 | KMT2A (0.35) | KMT2AALDH1A1RAB9AMEN1HPGD | |
| SCHEMBL5558771 | 0.79 | ALDH1A1 (0.39) | KMT2AALDH1A1MEN1TP53MAPT | |
| Formic Acid SCHEMBL4976263 | 0.77 | HSD11B1 (0.34) | KMT2AALDH1A1RAB9AMEN1TP53 | |
| SCHEMBL5563746 | 0.74 | MEN1 (0.38) | KMT2AALDH1A1MEN1TP53MAPT | |
| SCHEMBL5569980 | 0.71 | LMNA (0.38) | KMT2AALDH1A1RAB9AMEN1TP53 | |
| SCHEMBL4977670 | 0.70 | P2RX3 (0.36) | ALDH1A1RAB9ATP53MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223771-B2 | Tricyclic imidazopyridines | ALTANA PHARMA AG (DE) | 2007-05-29 | — | — | US | disclosed |
| EP-1419163-B9 | TRICYCLIC IMIDAZOPYRIDINES | ALTANA PHARMA AG (DE) | 2005-11-09 | — | — | EP | disclosed |
| EP-1419163-B1 | TRICYCLIC IMIDAZOPYRIDINES | ALTANA PHARMA AG (DE) | 2005-06-15 | — | — | EP | disclosed |
| US-20050049272-A1 | Gastrointestinal disorders; inhibiting gastric acid secretion; such as 2,3-dimethyl-9-(2-ethyl-6-methyl-phenyl)-7H-8,9-dihydro-pyrano[2,3-c]-imidazo[1,2-a]pyridine-6-(N,N-diethyl)carbamide | ALTANA PHARMA AG (DE) | 2005-03-03 | — | — | US | disclosed |
| EP-1419163-A1 | TRICYCLIC IMIDAZOPYRIDINES | ALTANA Pharma AG (DE) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003014123-A1 | TRICYCLIC IMIDAZOPYRIDINES | ALTANA PHARMA AG (DE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049272-A1 | Gastrointestinal disorders; inhibiting gastric acid secretion; such as 2,3-dimethyl-9-(2-ethyl-6-methyl-phenyl)-7H-8,9-dihydro-pyrano[2,3-c]-imidazo[1,2-a]pyridine-6-(N,N-diethyl)carbamide | GIPR, GRPR, PGC | KMT2A 1905/4885ALDH1A1 1670/4885RAB9A 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.